News Feed Item

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation





LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation


GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation". The Alzheimer's Disease (AD) market is characterized by a lack of products with strong disease-modifying properties and a number of high-profile product failures in late stages of development over recent years. In addition, recent or impending patent expiries for all of the four currently marketed products and a late-stage pipeline with limited-to-moderate prospects are expected to impede growth over the next few years. In the medium-term future, the market is expected to be characterized by substantial generic competition and overall decline. However, the current development pipeline shows signs of meaningful innovation, although the vast majority of these products are currently in the early stages of development. Despite one of the highest drug attrition rates across the industry, a number of innovative and potentially disease-modifying therapeutics are likely to enter the market and translate recent insights into the etiology of AD combined with an earlier therapeutic intervention into better products, which will begin to transform the AD market towards the end of the decade.


- A brief introduction to AD etiology, pathogenesis, diagnosis, and treatment regimes
- Profiling of the marketed products in the AD market, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses
- Comprehensive review of the pipeline for AD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type, and molecular target.
- Additional in-depth analysis of pipeline drug clinical trials, analyzed by phase, molecule type, trial size, trial duration and program failure rate, for each molecule type and mechanism of action
- Multi-scenario forecast data for the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers of and barriers to market growth
- Analysis of the licensing and co-development deals landscape

Reasons to buy

- Understand the different levels of AD therapies, from early-stage or mild AD to severe AD
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe trends in terms of clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for AD therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the AD therapeutics market
Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Symptoms 8
2.2 Etiology 9
2.3 Pathophysiology 10
2.3.1 Amyloidosis 10
2.3.2 Tau Hyperphosphorylation 10
2.4 Comorbidities/Complications 11
2.5 Diagnosis 11
2.5.1 Physical Examination 12
2.5.2 Mini Mental State Exam 12
2.5.3 Alzheimer's Disease Assessment Scale-cognitive 14
2.5.4 Alzheimer's Disease Co-operative Study – Activities of Daily Living Inventory 15
2.5.5 Other Diagnostic Tests 15
2.5.6 Blood Tests 15
2.5.7 Imaging Tests 15
2.5.8 Lumbar Puncture 15
2.5.9 Disease Biomarkers 16
2.5.10 Biomarker Market 17
2.6 Prognosis 18
2.7 Treatment Options 18
2.7.1 Treatment Algorithm 19
2.7.2 Non-Pharmacological Treatments 19
3 Marketed Products 20
3.1 Namenda/Axura/Memary (memantine), Merz Pharma/Lundbeck/Forest Laboratories/Daiichi Sankyo 20
3.2 Aricept (donepezil), Eisai Inc. 21
3.3 Exelon (rivastigmine), Novartis AG 22
3.4 Razadyne (galantamine), Janssen Pharmaceuticals 22
3.5 Cognex (tacrine), Shiniogi Inc. 23
3.6 Unmet Need 24
4 Pipeline for Alzheimer's Disease Therapeutics 25
4.1 Overall Pipeline 25
4.2 Mechanisms of Action within the AD Pipeline 27
4.3 Clinical Trials 29
4.3.1 Clinical Trial Failure Rate 29
4.3.2 Clinical Trial Size 33
4.3.3 Clinical Trial Duration 35
4.4 Notable Pipeline Drugs 38
4.4.1 Solanezumab – Eli Lilly and Company 38
4.4.2 LMTX (Methylene Blue) – TauRX Therapeutics Ltd. 39
4.4.3 RG-1540 (gantenerumab) – Roche 39
4.4.4 AD-02 – AFFiRiS AG 40
4.4.5 MK-8931 – Merck & Co. 41
4.4.6 CAD-106 – Novartis AG 41
4.4.7 LuAE58054 – Lundbeck 42
4.4.8 Crenezumab (RG7412) – Genentech 42
4.5 Conclusion 42
5 Market Forecast to 2019 44
5.1 Geographical Markets 44
5.1.1 Key Developed Markets 44
5.1.2 US 47
5.1.3 Leading Five EU Countries (EU5) 49
5.1.4 Japan 53
5.2 Drivers and Barriers 55
5.2.1 Drivers 55
5.2.2 Barriers 56
6 Deals and Strategic Consolidations 58
6.1 Key Licensing Deals 58
6.1.1 Forest Laboratories Inc. Enters into Agreement with Adamas Pharmaceuticals Inc. 60
6.1.2 AC Immune SA Enters into an Agreement with Genentech Inc. 60
6.1.3 Cephalon Inc. Enters into Agreement with Mesoblast Limited 60
6.1.4 Acadia Pharmaceuticals Inc. Enters into Agreement with Biovail Laboratories International SRL 60
6.1.5 Astellas Pharma Inc. enters into Agreement with CoMentis Inc. 61
6.2 Key Co-development Deals 61
6.2.1 Evotec AG Enters into Agreement with F. Hoffman-La Roche Ltd. 63
6.2.2 Alectos Therapeutics Inc. Enters into Agreement with Merck & Co. Inc. 63
6.2.3 Targacept Inc. Expands Agreement with AstraZeneca PLC. 63
6.2.4 GlaxoSmithKline Enters into an Agreement with Epix Pharmaceuticals 64
7 Appendix 65
7.1 All Pipeline Drugs by Phase – Tables 65
7.2 Market forecast to 2019 - Tables 81
7.3 References 84
7.4 Abbreviations 87
7.5 Methodology 89
7.6 Secondary Research 89
7.7 Therapeutic Landscape 90
7.8 Contact Us 90
7.9 Disclaimer 90

List of Tables

Table 1: Alzheimer's Disease, Global, All Pipeline Products (Discovery) 65
Table 2: Alzheimer's Disease, Global, All Pipeline Products (Preclinical) 68
Table 3: Alzheimer's Disease, Global, All Pipeline Products (Phase I) 76
Table 4: Alzheimer's Disease, Global, All Pipeline Products (Phase II) 79
Table 5: Alzheimer's Disease, Global, All Pipeline Products (Phase III) 81
Table 6: Alzheimer's Disease, Global, Market Forecast, 2012–2019 81
Table 7: Alzheimer's Disease, US, Market Forecast, 2012–2019 81
Table 8: Alzheimer's Disease, UK, Market Forecast, 2012–2019 82
Table 9: Alzheimer's Disease, France, Market Forecast, 2012–2019 82
Table 10: Alzheimer's Disease, Germany, Market Forecast, 2012–2019 82
Table 11: Alzheimer's Disease, Italy, Market Forecast, 2012–2019 83
Table 12: Alzheimer's Disease, Spain, Market Forecast, 2012–2019 83
Table 13: Alzheimer's Disease, Japan, Market Forecast, 2012–2019 83

List of Figures

Figure 1: Mini-Mental State Exam 13
Figure 2: Alzheimer's Disease Assessment Scale Cognitive Subscale 14
Figure 3: Alzheimer's Disease, Overall Pipeline 26
Figure 4: Alzheimer's Disease, Mechanisms of Action in the Pipeline, 2006–2013 29
Figure 5: Alzheimer's Disease, Failure Rates of Clinical Trials, 2006–2013 30
Figure 6: Alzheimer's Disease, Failure Rates by Mechanism of Action, 2006–2013 31
Figure 7: Alzheimer's Disease, Reasons for Clinical Trial Failure, 2006–2013 32
Figure 8: Alzheimer's Disease, Clinical Trial Size by Phase, 2006–2013 33
Figure 9: Alzheimer's Disease, Clinical Trial Size by Molecule Type, 2006–2013 34
Figure 10: Alzheimer's Disease, Clinical Trial Duration by Phase, 2006–2013 35
Figure 11: Alzheimer's Disease, Clinical Trial Duration by Molecule Type, 2006–2013 36
Figure 12: Alzheimer's Disease, Global, 2012–2019 46
Figure 13: Alzheimer's Disease, US, 2012–2019 48
Figure 14: Alzheimer's Disease, EU5, Patient Number ('000) 2012–2019 50
Figure 15: Alzheimer's Disease, EU5, Annual Cost of Treatment ($), 2012–2019 51
Figure 16: Alzheimer's Disease, EU5, Market Size ($m), 2012–2019 52
Figure 17: Alzheimer's Disease, Japan, 2012–2019 54
Figure 18: Alzheimer's Disease, Global, Licensing Deals by Region and Year, 2012–2019 58
Figure 19: Alzheimer's Disease, Global, Licensing Deals by Phase and Molecule Type, 2012–2019 59
Figure 20: Alzheimer's Disease, Global, Co-development Deals by Region and Year, 2012–2019 61
Figure 21: Alzheimer's Disease, Global, Co-development Deals by Phase and Molecule Type, 2006–2013 62

Read the full report:
Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of So...
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys Service consists of a public key service and a private key escrow service. 

SYS-CON Events announced today that eCube Systems, the leading provider of modern development tools and best practices for Continuous Integration on OpenVMS, will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. eCube Systems offers a family of middleware products and development tools that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
Amazon has gradually rolled out parts of its IoT offerings, but these are just the tip of the iceberg. In addition to optimizing their backend AWS offerings, Amazon is laying the ground work to be a major force in IoT - especially in the connected home and office. In his session at @ThingsExpo, Chris Kocher, founder and managing director of Grey Heron, explained how Amazon is extending its reach to become a major force in IoT by building on its dominant cloud IoT platform, its Dash Button strat...
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessi...
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
DevOps is speeding towards the IT world like a freight train and the hype around it is deafening. There is no reason to be afraid of this change as it is the natural reaction to the agile movement that revolutionized development just a few years ago. By definition, DevOps is the natural alignment of IT performance to business profitability. The relevance of this has yet to be quantified but it has been suggested that the route to the CEO’s chair will come from the IT leaders that successfully ma...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.